keyword
MENU ▼
Read by QxMD icon Read
search

Dengue vaccine

keyword
https://www.readbyqxmd.com/read/28821561/zika-virus-activates-de-novo-and-cross-reactive-memory-b-cell-responses-in-dengue-experienced-donors
#1
Thomas F Rogers, Eileen C Goodwin, Bryan Briney, Devin Sok, Nathan Beutler, Alexander Strubel, Rebecca Nedellec, Khoa Le, Michael E Brown, Dennis R Burton, Laura M Walker
Zika virus (ZIKV) shares a high degree of homology with dengue virus (DENV), suggesting that preexisting immunity to DENV could affect immune responses to ZIKV. We have tracked the evolution of ZIKV-induced B cell responses in three DENV-experienced donors. The acute antibody (plasmablast) responses were characterized by relatively high somatic hypermutation and a bias toward DENV binding and neutralization, implying the early activation of DENV clones. A DENV-naïve donor in contrast showed a classical primary plasmablast response...
August 18, 2017: Science Immunology
https://www.readbyqxmd.com/read/28820715/limited-transmission-potential-of-takeda-s-tetravalent-dengue-vaccine-candidate-by-aedes-albopictus
#2
Elizabeth A Dietrich, Yee Tsuey Ong, Janae L Stovall, Hansi Dean, Claire Y-H Huang
Recombinant live-attenuated chimeric tetravalent dengue vaccine viruses, TDV-1, -2, -3, and -4, contain the premembrane and envelope genes of dengue virus serotypes 1-4 in the replicative background of the attenuated dengue virus type-2 (DENV-2) PDK-53 vaccine strain. Previous results have shown that these recombinant vaccine viruses demonstrate limited infection and dissemination in Aedes aegypti and are unlikely to be transmitted by the primary mosquito vector of DENVs. In this report, we expand this analysis by assessing vector competence of all four serotypes of the TDV virus in Aedes albopictus, the secondary mosquito vector of DENVs...
August 14, 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28806786/an-economic-evaluation-of-vector-control-in-the-age-of-a-dengue-vaccine
#3
Christopher Fitzpatrick, Alexander Haines, Mathieu Bangert, Andrew Farlow, Janet Hemingway, Raman Velayudhan
INTRODUCTION: Dengue is a rapidly emerging vector-borne Neglected Tropical Disease, with a 30-fold increase in the number of cases reported since 1960. The economic cost of the illness is measured in the billions of dollars annually. Environmental change and unplanned urbanization are conspiring to raise the health and economic cost even further beyond the reach of health systems and households. The health-sector response has depended in large part on control of the Aedes aegypti and Ae...
August 14, 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28802204/humanized-mouse-models-to-study-human-cell-mediated-and-humoral-responses-to-dengue-virus
#4
REVIEW
Anuja Mathew
Several candidate dengue virus vaccines are in clinical trials and show promise as an effective measure to control dengue. However, it is becoming clear that additional vaccine candidates may be needed as there is concern about the durability of the immune response to all four serotypes of vaccine components and efficacy varies dependent on the immune status of the individual. The lack of an appropriate animal model to mimic human dengue has deterred the development of vaccines and anti-viral therapies to dengue virus...
August 9, 2017: Current Opinion in Virology
https://www.readbyqxmd.com/read/28794424/virus-like-particles-that-display-zika-virus-envelope-protein-domain-iii-induce-potent-neutralizing-immune-responses-in-mice
#5
Ming Yang, Huafang Lai, Haiyan Sun, Qiang Chen
Several Zika virus (ZIKV) vaccine candidates have recently been described which use inactivated whole virus, DNA or RNA that express the virus' Envelope (E) glycoprotein as the antigen. These were successful in stimulating production of virus-targeted antibodies that protected animals against ZIKV challenges, but their use potentially will predispose vaccinated individuals to infection by the related Dengue virus (DENV). We have devised a virus like particle (VLP) carrier based on the hepatitis B core antigen (HBcAg) that displays the ZIKV E protein domain III (zDIII), and shown that it can be produced quickly and easily purified in large quantities from Nicotiana benthamiana plants...
August 9, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28794181/a-neutralization-assay-for-zika-and-dengue-viruses-using-a-real-time-pcr-based-endpoint-assessment
#6
Heather L Wilson, Thomas Tran, Julian Druce, Myrielle Dupont-Rouzeyrol, Michael Catton
The global spread and infective complications of Zika virus (ZKV) and Dengue virus (DENV) have made them flaviviruses of public health concern. Serological diagnosis can be challenging due to antibody cross-reactivity, particularly in secondary flavivirus infections or when there is a history of flavivirus vaccination. The virus neutralization assay is considered to be the most specific assay for measurement of anti-flavivirus antibodies. This study describes an assay where neutralization endpoint is measured by real-time PCR, providing results within 72 hours...
August 9, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28791613/oleic-acid-enhances-dengue-virus-but-not-dengue-virus-like-particle-production-from-mammalian-cells
#7
Suwipa Ramphan, Sathiporn Suksathan, Nitwara Wikan, Puey Ounjai, Kanpong Boonthaworn, Poramate Rimthong, Tapanee Kanjanapruthipong, Suchin Worawichawong, Anan Jongkaewwattana, Nuttaporn Wongsiriroj, Duncan R Smith
Despite the recent introduction of a commercial vaccine, the mosquito-transmitted dengue virus is still a worldwide public health problem. Based on the live attenuated vaccine strategy, the commercial vaccine has a less than optimal protective profile. Virus-like particles (VLPs) offer an attractive alternate vaccination strategy due to the effectively native presentation of epitopes in the absence of any infectious genetic material. However, the production of amounts of VLP in a platform that can support commercial development remains a major obstacle...
August 8, 2017: Molecular Biotechnology
https://www.readbyqxmd.com/read/28791258/prevention-and-control-strategies-to-counter-dengue-virus-infection
#8
REVIEW
Irfan A Rather, Hilal A Parray, Jameel B Lone, Woon K Paek, Jeongheui Lim, Vivek K Bajpai, Yong-Ha Park
Dengue is currently the highest and rapidly spreading vector-borne viral disease, which can lead to mortality in its severe form. The globally endemic dengue poses as a public health and economic challenge that has been attempted to suppress though application of various prevention and control techniques. Therefore, broad spectrum techniques, that are efficient, cost-effective, and environmentally sustainable, are proposed and practiced in dengue-endemic regions. The development of vaccines and immunotherapies have introduced a new dimension for effective dengue control and prevention...
2017: Frontiers in Cellular and Infection Microbiology
https://www.readbyqxmd.com/read/28791003/dengue-virus-glycosylation-what-do-we-know
#9
REVIEW
Sally S L Yap, Terry Nguyen-Khuong, Pauline M Rudd, Sylvie Alonso
In many infectious diseases caused by either viruses or bacteria, pathogen glycoproteins play important roles during the infection cycle, ranging from entry to successful intracellular replication and host immune evasion. Dengue is no exception. Dengue virus glycoproteins, envelope protein (E) and non-structural protein 1 (NS1) are two popular sub-unit vaccine candidates. E protein on the virion surface is the major target of neutralizing antibodies. NS1 which is secreted during DENV infection has been shown to induce a variety of host responses through its binding to several host factors...
2017: Frontiers in Microbiology
https://www.readbyqxmd.com/read/28771479/direct-cost-of-dengue-hospitalization-in-zhongshan-china-associations-with-demographics-virus-types-and-hospital-accreditation
#10
Jing Hua Zhang, Juan Yuan, Tao Wang
BACKGROUND: Zhongshan City of Guangdong Province (China) is a key provincial and national level area for dengue fever prevention and control. The aim of this study is to analyze how the direct hospitalization costs and the length of stay of dengue hospitalization cases vary according to associated factors such as the demographics, virus types and hospital accreditation. METHOD: This study is based on retrospective census data from the Chinese National Disease Surveillance Reporting System...
August 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28765561/antibodies-against-modified-ns1-wing-domain-peptide-protect-against-dengue-virus-infection
#11
Yen-Chung Lai, Yung-Chun Chuang, Ching-Chuan Liu, Tzong-Shiann Ho, Yee-Shin Lin, Robert Anderson, Trai-Ming Yeh
Dengue is the most common mosquito-transmitted viral infection for which an improved vaccine is still needed. Although nonstructural protein-1 (NS1) immunization can protect mice against dengue infection, molecular mimicry between NS1 and host proteins makes NS1-based vaccines challenging to develop. Based on the epitope recognized by the anti-NS1 monoclonal Ab (mAb) 33D2 which recognizes a conserved NS1 wing domain (NS1-WD) region but not host proteins, we synthesized a modified NS1-WD peptide to immunize mice...
August 1, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28758854/3d-qsar-pharmacophore-based-virtual-screening-molecular-docking-and-molecular-dynamics-simulation-toward-identifying-lead-compounds-for-ns2b-ns3-protease-inhibitors
#12
Pei H Luo, Xuan R Zhang, Lan Huang, Lun Yuan, Xang Z Zhou, X Gao, Ling S Li
NS2B-NS3 protease has been identified to serve as lead drug design target due to its significant role in West Nile viral (WNV) and dengue virus (DENV) reproduction and replication. There are currently no approved chemotherapeutic drugs and effective vaccines to inhibit DENV and WNV infections. In this work, 3D-QSAR pharmacophore model has been developed to discover potential inhibitory candidates. Validation through Fischer's model and decoy test indicate that the developed 3D pharmacophore model is highly predictive for DENV inhibitors, which was then employed to screen ZINC chemical library to obtain reasonable hits...
October 2017: Journal of Receptor and Signal Transduction Research
https://www.readbyqxmd.com/read/28758824/vaccine-development-and-trials-in-low-and-lower-middle-income-countries-key-issues-advances-and-future-opportunities
#13
Amy Grenham, Tonya Villafana
Over the past ten years there has been an increase in the number of vaccine clinical studies conducted in resource limited countries. These include vaccine trials for diseases such as malaria and dengue fever which are endemic to many low and lower-middle income countries. Concurrent with the increase in the number of trials, has been the increase and improvement in local infrastructure to enable the appropriate conduct and oversight of these trials in these settings, including strengthening of local scientific capabilities, ethical and regulatory oversight...
July 31, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28758019/current-trends-in-zika-vaccine-development
#14
EDITORIAL
Francisco A Lagunas-Rangel, Martha E Viveros-Sandoval, Arturo Reyes-Sandoval
The Zika virus (ZIKV) was first isolated in 1947 in Uganda. While it took 60 years for this virus to cause major outbreaks, an important shift in its ability to cause epidemics took place in the first and second decades of the this century: in 2007 in Yap Island, Micronesia, followed by French Polynesia in 2013 and, finally in 2015 and 2016, when ZIKV infections occurred throughout South America, Central America and the Caribbean, spreading rapidly to reach North America in just a single year. No licensed prophylactic vaccine is yet available but recent efforts towards the development of a vaccine have been remarkable from both the private and public sectors and include new candidate vaccines ranging from the classical live-attenuated or inactivated vaccines to more sophisticated approaches such as mRNA or genetically engineered viral platforms...
July 1, 2017: Journal of Virus Eradication
https://www.readbyqxmd.com/read/28757058/immune-correlates-of-protection-for-dengue-state-of-the-art-and-research-agenda
#15
Leah C Katzelnick, Eva Harris
Dengue viruses (DENV1-4) are mosquito-borne flaviviruses estimated to cause up to ∼400 million infections and ∼100 million dengue cases each year. Factors that contribute to protection from and risk of dengue and severe dengue disease have been studied extensively but are still not fully understood. Results from Phase 3 vaccine efficacy trials have recently become available for one vaccine candidate, now licensed for use in several countries, and more Phase 2 and 3 studies of additional vaccine candidates are ongoing, making these issues all the more urgent and timely...
July 27, 2017: Vaccine
https://www.readbyqxmd.com/read/28754189/progress-and-works-in-progress-update-on-flavivirus-vaccine-development
#16
REVIEW
Matthew H Collins, Stefan W Metz
Most areas of the globe are endemic for at least one flavivirus, putting billions at risk for infection. This diverse group of viral pathogens causes a range of manifestations in humans from asymptomatic infection to hemorrhagic fever to encephalitis to birth defects and even death. Many flaviviruses are transmitted by mosquitos and have expanded in geographic distribution in recent years, with dengue virus being the most prevalent, infecting approximately 400 million people each year. The explosive emergence of Zika virus in Latin America in 2014 refocused international attention on this medically important group of viruses...
July 25, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28753671/self-reported-infections-during-international-travel-and-notifiable-infections-among-returning-international-travellers-sweden-2009-2013
#17
Viktor Dahl, Anders Wallensten
We studied food and water-borne diseases (FWDs), sexually transmitted diseases (STDs), vector-borne diseases (VBDs) and diseases vaccinated against in the Swedish childhood vaccination programme among Swedish international travellers, in order to identify countries associated with a high number of infections. We used the national database for notifiable infections to estimate the number of FWDs (campylobacteriosis, salmonellosis, giardiasis, shigellosis, EHEC, Entamoeba histolytica, yersinosis, hepatitis A, paratyphoid fever, typhoid fever, hepatitis E, listeriosis, cholera), STIs (chlamydia, gonorrhoea and acute hepatitis B), VBDs (dengue fever, malaria, West Nile fever, Japanese encephalitis and yellow fever) and diseases vaccinated against in the Swedish childhood vaccination programme (pertussis, measles, mumps, rubella, diphtheria) acquired abroad 2009-2013...
2017: PloS One
https://www.readbyqxmd.com/read/28750738/dengue-virus-evades-aav-mediated-neutralizing-antibody-prophylaxis-in-rhesus-monkeys
#18
Diogo M Magnani, Michael J Ricciardi, Varian K Bailey, Martin J Gutman, Núria Pedreño-Lopez, Cassia G T Silveira, Helen S Maxwell, Aline Domingues, Lucas Gonzalez-Nieto, Qin Su, Ruchi M Newman, Melissa Pack, Mauricio A Martins, José M Martinez-Navio, Sebastian P Fuchs, Eva G Rakasz, Todd M Allen, Stephen S Whitehead, Dennis R Burton, Guangping Gao, Ronald C Desrosiers, Esper G Kallas, David I Watkins
Development of vaccines against mosquito-borne Flaviviruses is complicated by the occurrence of antibody-dependent enhancement (ADE), which can increase disease severity. Long-term delivery of neutralizing antibodies (nAbs) has the potential to effectively block infection and represents an alternative to vaccination. The risk of ADE may be avoided by using prophylactic nAbs harboring amino acid mutations L234A and L235A (LALA) in the immunoglobulin G (IgG) constant region. Here, we used recombinant adeno-associated viruses (rAAVs) to deliver the anti-dengue virus 3 (DENV3) nAb P3D05...
July 24, 2017: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/28748091/the-tetravalent-formulation-of-domain-iii-capsid-proteins-recalls-memory-b-and-t-cell-responses-induced-in-monkeys-by-an-experimental-dengue-virus-infection
#19
Lázaro Gil, Laura Lazo, Iris Valdés, Edith Suzarte, Phuong Yen, Rosa Ramírez, Mayling Álvarez, Le T Dung, Karem Cobas, Ernesto Marcos, Yusleidi Pérez, María G Guzmán, Ngyen D Hien, Gerardo Guillén, Lisset Hermida
Tetra DIIIC is a vaccine candidate against dengue virus (DENV) composed by four chimeric proteins that fuse the domain III of the envelope protein of each virus to the corresponding capsid protein. Containing B- and T-cell epitopes, these proteins form aggregates after the incubation with an immunostimulatory oligodeoxynucleotide, and their tetravalent formulation induces neutralizing antibodies and cellular immune response in mice and monkeys. Also, Tetra DIIIC protects mice after challenge with each DENV, and the monovalent formulation obtained from DENV-2 protects monkeys upon homologous viral challenge...
June 2017: Clinical & Translational Immunology
https://www.readbyqxmd.com/read/28742857/dna-immunisation-with-dengue-virus-e-protein-domains-i-ii-but-not-domain-iii-enhances-zika-west-nile-and-yellow-fever-virus-infection
#20
Jose L Slon Campos, Monica Poggianella, Sara Marchese, Monica Mossenta, Jyoti Rana, Francesca Arnoldi, Marco Bestagno, Oscar R Burrone
Dengue virus (DENV), the causative agent of dengue disease, is among the most important mosquito-borne pathogens worldwide. DENV is composed of four closely related serotypes and belongs to the Flaviviridae family alongside other important arthropod-borne viral pathogens such as Zika virus (ZIKV), West Nile virus (WNV) and Yellow Fever virus (YFV). After infection, the antibody response is mostly directed to the viral E glycoprotein which is composed of three structural domains named DI, DII and DIII that share variable degrees of homology among different viruses...
2017: PloS One
keyword
keyword
42416
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"